Avicanna(OTC) AVCNF

Current Price$0.10

Market Cap$11.64M

Since IPO (2019)-96%

5 Year-86%

1 Year-49%

1 Month+14%

Avicanna last closing stock price
Metric	Price	Date
Last close	USD 0.10	2026-07-22

Avicanna stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+14.95%	USD 0.09	2026-07-15
1 month	+14.35%	USD 0.09	2026-06-22
3 month	-11.1%	USD 0.11	2026-04-23
Year to date	-37.43%	USD 0.16	2025-12-31
1 year	-49.29%	USD 0.20	2025-07-22
3 year	-54.68%	USD 0.22	2023-07-21
5 year	-85.51%	USD 0.70	2021-07-21
Since inception	-96.31%	USD 2.75	2019-09-03

Avicanna Financials at a Glance

Market Cap

$11.64M

Revenue (TTM)

CA$25.85M

Net Income (TTM)

-CA$3.59M

EPS (TTM)

-$0.02

P/E Ratio

-4.07

Dividend

$0.00

Beta (Volatility)

0.71 (Low)

Dividend

$0.00

Beta (Volatility)

0.71 (Low)

Price

$0.10

Volume

4,000

Open

$0.09

Price

$0.10

Volume

4,000

Open

$0.09

Previous Close

$0.10

Daily Range

$0.09 - $0.10

52-Week Range

$0.07 - $0.24

Estimated Earnings Date

Aug 12, 2026

Dividend

$0.00

Beta (Volatility)

0.71 (Low)

Price

$0.10

Volume

4,000

Open

$0.09

Previous Close

$0.10

Daily Range

$0.09 - $0.10

52-Week Range

$0.07 - $0.24

Estimated Earnings Date

Aug 12, 2026

AVCNF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Avicanna

Avicanna Inc. is a biopharmaceutical company focused on the research and development of scientifically-backed products for the global consumer health and pharmaceutical sectors. The company is in its commercial phase and collaborates with Canadian academic and medical institutions to advance its innovative product offerings.

Products and Services

RHO Phyto: Medical and wellness products containing cannabinoids like CBD, CBG, and THC
Pura H&W and Pura Earth: Functional CBD-infused derma-cosmetic and topical products
Aureus: A range of cannabis and hemp-derived goods, including extracts and formulations

Growth Outlook

Recent revenue of CAD 6.7 million indicates strong market demand
Partnerships with academic institutions enhance research capabilities
Development of pharmaceutical solutions for chronic pain and neurological disorders

Financial Highlights

Trailing twelve months (TTM) revenue of CAD 26.5 million shows consistent growth
Gross profit margin of 51.3% reflects effective cost management
Operating expenses decreased by 5% in the latest quarter

Avicanna Inc. is positioned in the healthcare sector, specifically within drug manufacturing, and has established a diverse portfolio of products. The company's scientific approach to product development, combined with its partnerships, supports its growth strategy. Recent financial performance indicates a positive trajectory, with significant revenue generation and a solid gross profit margin. The focus on developing innovative pharmaceutical solutions further enhances the company's potential for future growth.

AI Generated • Jun 26, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

112

CEO

Aras Azadian, MBA

Website

www.avicanna.com

Headquarters

Toronto, ON M5G 1V2, CA

AVCNF Financials

Key Financial Metrics (TTM)

Gross Margin

51.34%

Operating Margin

-12.95%

Net Income Margin

-13.90%

Return on Equity

-116.09%

Return on Capital

-95.51%

Return on Assets

-16.26%

Earnings Yield

-24.57%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$11.64M

Shares Outstanding

125.79M

Volume

4.00K

Avg. Volume

101.58K

Financials (TTM)

Gross Profit

CA$13.27M

Operating Income

-CA$3.35M

EBITDA

-CA$2.63M

Operating Cash Flow

-CA$2.12M

Capital Expenditure

-CA$128.86K

Free Cash Flow

-CA$2.25M

Cash & ST Invst.

CA$373.06K

Total Debt

CA$0.00

Avicanna Performance Analysis

Avicanna annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	CAD 3,109,321	19.3%
2023	2023-12-31	CAD 12,441,020	300.1%
2024	2024-12-31	CAD 18,583,890	49.4%
2025	2025-12-31	CAD 18,234,383	-1.9%

Avicanna sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	-2.6%
Q3	2025-09-30	3.9%
Q4	2025-12-31	3.1%
Q1	2026-03-31	1.6%

Avicanna annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	CAD -0.17	-46.2%
2023	2023-12-31	CAD -0.07	-60.4%
2024	2024-12-31	CAD -0.03	-57.8%
2025	2025-12-31	CAD -0.02	-39.2%

Avicanna sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	-1000.0%
Q3	2025-09-30	-84.1%
Q4	2025-12-31	32.8%
Q1	2026-03-31	37.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

CA$6.70M

+5.9%

Gross Profit

CA$3.50M

-2.8%

Gross Margin

52.29%

N/A

Market Cap

$11.64M

N/A

Market Cap/Employee

$103.89K

N/A

Employees

112

N/A

Net Income

-CA$583.15K

-880.4%

EBITDA

-CA$324.55K

-208.4%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

CA$373.06K

-18.3%

Total Debt

CA$0.00

-100.0%

Accounts Receivable

CA$3.48M

+46.6%

Inventory

CA$4.10M

-5.7%

Long Term Debt

CA$0.00

N/A

Short Term Debt

CA$0.00

-100.0%

Return on Assets

-16.26%

N/A

Return on Invested Capital

-25.02%

N/A

Free Cash Flow

-CA$971.85K

-516.2%

Operating Cash Flow

-CA$958.83K

-5321.7%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

IZOZFIzotropic Corporation

IZOZFIzotropic Corporation$0.19+8.09%

CNTMFFluent Corp.

CNTMFFluent Corp.$0.03-6.67%

ISCNFIsracann Biosciences Inc.

ISCNFIsracann Biosciences Inc.$0.00+0.00%

MEDIFMediPharm Labs Corp.

MEDIFMediPharm Labs Corp.$0.06+1.79%

RAPHRaphael Pharmaceutical Inc.

RAPHRaphael Pharmaceutical Inc.$1.40+0.00%

GBLPGlobal Pharmatech, Inc.

GBLPGlobal Pharmatech, Inc.$0.08+0.00%

CWBHFCharlotte's Web Holdings, Inc.

CWBHFCharlotte's Web Holdings, Inc.$0.22-2.42%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TAT&T

TAT&T$23.04+0.04%

ONDSOndas

ONDSOndas$8.00+0.04%

SMCISuper Micro Computer

SMCISuper Micro Computer$30.56+0.20%

AALAmerican Airlines Group

AALAmerican Airlines Group$14.79-0.03%

PATHUiPath

PATHUiPath$10.70-0.11%

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$115.26-0.07%

SOFISoFi Technologies

SOFISoFi Technologies$17.07-0.03%

Questions About AVCNF

What is the current price of Avicanna?

Avicanna is trading at $0.10 per share.

What is the 52-week range for Avicanna?

Over the past 52 weeks, Avicanna has traded between $0.07 and $0.24.

How much debt does Avicanna have?

As of the most recent reporting period, Avicanna reported total debt of CA$0.00.

How much cash does Avicanna have on hand?

Avicanna reported CA$266.64K in cash and cash equivalents in its most recent financial results.

What is Avicanna’s dividend yield?

Avicanna does not currently have a dividend yield.

Avicanna(OTC) AVCNF

Avicanna Financials at a Glance

AVCNF News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Avicanna

AVCNF Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Avicanna Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About AVCNF

What is the current price of Avicanna?

What is the 52-week range for Avicanna?

How much debt does Avicanna have?

How much cash does Avicanna have on hand?

What is Avicanna’s dividend yield?

Premium Investing Services